CNS Pharmaceuticals, Inc.
CNSP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $9 | $14 | $9 | $10 |
| G&A Expenses | $0 | $5 | $0 | $0 |
| SG&A Expenses | $6 | $5 | $6 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $15 | $19 | $15 | $14 |
| Operating Income | -$15 | -$19 | -$15 | -$14 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | -$0 | -$0 |
| Pre-Tax Income | -$15 | -$19 | -$15 | -$14 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$15 | -$19 | -$15 | -$14 |
| % Margin | – | – | – | – |
| EPS | -38.87 | -60 | -134.64 | -6.36 |
| % Growth | 35.2% | 55.4% | -2,017% | – |
| EPS Diluted | -38.87 | -60 | -134.64 | -6.36 |
| Weighted Avg Shares Out | 0 | 6 | 2 | 1 |
| Weighted Avg Shares Out Dil | 0 | 6 | 2 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$15 | -$19 | -$15 | -$14 |
| % Margin | – | – | – | – |